AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34628232 — intervention group
Group type: COMPARATOR
Intervention: Open weighing
Number of subjects: 53
Study 34628232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Blind and Open weighing)
Number of subjects: 53
Study 34674574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized tromethamine (THAM)
Number of subjects: 32
Study 34674574 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 32
Study 32846806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) therapy
Number of subjects: 0
Study 32846806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NHF therapy)
Number of subjects: 0
Study 35465804 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared governance intervention
Number of subjects: 318
Study 35465804 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 318
Study 34872628 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study 34872628 — intervention group
Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 244
Study 36057390 — intervention group
Group type: COMPARATOR
Intervention: Three-staged invitation procedure (pre-notification, invitation, and one reminder)
Number of subjects: 59041
Study 36057390 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra reminder
Number of subjects: 59041
Study 36057390 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-staged invitation procedure (specifically for age group 50-59 years)
Number of subjects: 59041
Study 33849035 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 33849035 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 33849035 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 0
Study 33849035 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study 35137345 — intervention group
Group type: EXPERIMENTAL
Intervention: Choriomon® (10,000 IU)
Number of subjects: 26
Study 35137345 — intervention group
Group type: COMPARATOR
Intervention: Ovitrelle® (250 µg; 6500 IU)
Number of subjects: 26
Study 33333105 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake ≥232 mg/day
Number of subjects: 121374
Study 33333105 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake >480 mg/day
Number of subjects: 121374
Study 33333105 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake ≥321 mg/day
Number of subjects: 121374
Study 33333105 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake (general)
Number of subjects: 121374
Study 33333105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 121374
Study 34216838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 5 hours sleep opportunity per night for 9 nights
Number of subjects: 20
Study 34216838 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend Recovery (WR) - 5 hours sleep opportunity per night for 4 nights followed by ad libitum weekend recovery sleep
Number of subjects: 20
Study 34216838 — intervention group
Group type: COMPARATOR
Intervention: Control - 9 hours sleep per night
Number of subjects: 20
Study 34052092 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline instillation (NSI)
Number of subjects: 58
Study 34052092 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure recruitment manoeuvre (RM)
Number of subjects: 58
Study 34052092 — intervention group
Group type: COMPARATOR
Intervention: No normal saline instillation (no NSI)
Number of subjects: 58
Study 34052092 — intervention group
Group type: COMPARATOR
Intervention: No recruitment manoeuvre (no RM)
Number of subjects: 58
Study 35721180 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate-Remifentanil (RT-RF)
Number of subjects: 146
Study 35721180 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine-Remifentanil (Dex-RF)
Number of subjects: 146
Study 35721180 — intervention group
Group type: COMPARATOR
Intervention: Remimazolam Tosilate-Remifentanil (RT-RF) vs Dexmedetomidine-Remifentanil (Dex-RF)
Number of subjects: 146
Study 33006190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 33006190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35952357 — intervention group
Group type: EXPERIMENTAL
Intervention: ART adherence measured by hair tenofovir (TFV) levels post breastfeeding cessation
Number of subjects: 55
Study 35952357 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of hair TFV concentration
Number of subjects: 55
Study 35952357 — intervention group
Group type: EXPERIMENTAL
Intervention: Viremia frequency
Number of subjects: 55
Study 33687126 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal eosinophilia at baseline (D1 eosinophilia)
Number of subjects: 213
Study 33687126 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no duodenal eosinophilia)
Number of subjects: 213
Study 34757919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 256
Study 34757919 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 256
Study 34757919 — intervention group
Group type: COMPARATOR
Intervention: PM20D1, C18:1‐Leu and C18:1‐Phe levels
Number of subjects: 256
Study 35039263 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangfuyan capsule combined with antibiotics (azithromycin + metronidazole)
Number of subjects: 83
Study 35039263 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics (azithromycin + metronidazole) alone (control group)
Number of subjects: 83
Study 32130164 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Ambient Display (MAD)
Number of subjects: 16
Study 32130164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MAD)
Number of subjects: 16
Study 36420938 — intervention group
Group type: EXPERIMENTAL
Intervention: OL-HDF using FxCordiax HDF 800™
Number of subjects: 14
Study 36420938 — intervention group
Group type: EXPERIMENTAL
Intervention: Elisio 21HX™
Number of subjects: 14
Study 36420938 — intervention group
Group type: EXPERIMENTAL
Intervention: Theranova 500®
Number of subjects: 14
Study 34475873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Foralumab (100ug/day) given for 10 consecutive days with 6 mg dexamethasone given on days 1-3 (n=11)
Number of subjects: 39
Study 34475873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Foralumab alone (100ug/day) given for 10 consecutive days (n=12)
Number of subjects: 39
Study 34475873 — intervention group
Group type: COMPARATOR
Intervention: Control, no Foralumab (n=16)
Number of subjects: 39
Study 34475873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Foralumab (100ug/day) and Foralumab/Dexa treated subjects
Number of subjects: 39
Study 34475873 — intervention group
Group type: EXPERIMENTAL
Intervention: Foralumab treatment
Number of subjects: 39
Study 32933953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment for insomnia (CBT‐I) for 8 weeks plus 4 bimonthly booster sessions
Number of subjects: 130
Study 32933953 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene control group (SH)
Number of subjects: 130
Study 35320285 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health message reframing social distancing as recklessness rather than bravery
Number of subjects: 0
Study 35320285 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health message highlighting the need for everyone to take action to protect one another
Number of subjects: 0
Study 35853017 — intervention group
Group type: COMPARATOR
Intervention: [68Ga]Ga-PSMA-11
Number of subjects: 100
Study 35853017 — intervention group
Group type: COMPARATOR
Intervention: [18F]PSMA-1007
Number of subjects: 100
Study 35853017 — intervention group
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Number of subjects: 100
Study 33306114 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm email feedback program (2 emails with evidence-based information about nimodipine and individual prescription levels)
Number of subjects: 1811
Study 33306114 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 emails with general information about the risks of overprescription)
Number of subjects: 1811
Study 33306114 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (opened emails)
Number of subjects: 1811
Study 33306114 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 1811
Study 35863486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Solution (300 mg/5 ml twice daily)
Number of subjects: 339
Study 35863486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 5 ml twice daily)
Number of subjects: 339
Study 32511154 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 108
Study 32511154 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 108
Study 35275242 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair with intra-operative ultrasound (Group A)
Number of subjects: 91
Study 35275242 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous repair without intra-operative ultrasound (Group B)
Number of subjects: 91
Study 35275242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 32454239 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency‐induced thermotherapy (RFiTT) combined with transilluminated powered phlebectomy (TIPP)
Number of subjects: 200
Study 32454239 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping (HLS) combined with TIPP
Number of subjects: 200
Study 32454239 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency‐induced thermotherapy (RFiTT) combined with TIPP
Number of subjects: 200
Study 36228982 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, rewards-based physical activity intervention for 6 months
Number of subjects: 192
Study 36228982 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving educational materials, activity monitor, web-based interface access, rewards based on physical activity levels at the end of the intervention
Number of subjects: 192
Study 34916635 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fibre posts with composite resin restorations
Number of subjects: 141
Study 34916635 — intervention group
Group type: COMPARATOR
Intervention: Cast metal posts with metal-ceramic crowns
Number of subjects: 141
Study 34916635 — intervention group
Group type: COMPARATOR
Intervention: Crown re-cementation
Number of subjects: 141
Study 34916635 — intervention group
Group type: COMPARATOR
Intervention: Repair of resin restoration
Number of subjects: 141
Study 33204865 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 50
Study 33204865 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 50
Study 32134291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy adapted for patients with IBS (MBCT-IBS)
Number of subjects: 67
Study 32134291 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 67
Study 35553053 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibition (aCPI)
Number of subjects: 1518
Study 35553053 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1518
Study 35553053 — intervention group
Group type: COMPARATOR
Intervention: Simulation of observation arm with informative censoring
Number of subjects: 1518
Study 33334505 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL-T01
Number of subjects: 348
Study 33334505 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 348
Study 33634592 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-simulation hot debriefing (PSHD)
Number of subjects: 59
Study 33634592 — intervention group
Group type: COMPARATOR
Intervention: Cold debriefing (PSCD)
Number of subjects: 59
Study 33030515 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m2, days 1, 8, and 15 every 4 weeks)
Number of subjects: 60
Study 33030515 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with Bevacizumab (10 mg/kg, every 2 weeks for 6 cycles, followed by maintenance bevacizumab 15 mg/kg every 3 weeks)
Number of subjects: 60
Study 33030515 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with Bevacizumab
Number of subjects: 60
Study 36173407 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person proctoring (G2)
Number of subjects: 36
Study 36173407 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote proctoring (G3)
Number of subjects: 36
Study 36173407 — intervention group
Group type: COMPARATOR
Intervention: No assistance (G1)
Number of subjects: 36
Study 33754315 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.08 mg/kg) in severe kidney impairment requiring hemodialysis
Number of subjects: 78
Study 33754315 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.08 mg/kg) in moderate kidney impairment
Number of subjects: 78
Study 33754315 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.08 mg/kg) in severe kidney impairment
Number of subjects: 78
Study 33754315 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.08 mg/kg) in kidney impairment requiring hemodialysis
Number of subjects: 78
Study 33754315 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.08 mg/kg) in moderate hepatic impairment
Number of subjects: 78
Study 33754315 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.08 mg/kg) in mild hepatic impairment
Number of subjects: 78
Study 36363502 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) program
Number of subjects: 34
Study 36363502 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training (MIT)
Number of subjects: 34
Study 36363502 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 34
Study 34608713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) arthrocentesis
Number of subjects: 44
Study 34608713 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided (LMG) arthrocentesis
Number of subjects: 44
Study 34427452 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 94
Study 34427452 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 94
Study 35894080 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3 mg subcutaneously daily)
Number of subjects: 136
Study 35894080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 32715996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 335
Study 32715996 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 335
Study 32286149 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid prescription
Number of subjects: 901
Study 32286149 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pain
Number of subjects: 901
Study 32286149 — intervention group
Group type: EXPERIMENTAL
Intervention: Country-specific opioid underuse rates
Number of subjects: 901
Study 35339351 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS + Cognitive Stimulation (CS)
Number of subjects: 36
Study 35339351 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Cognitive Stimulation (CS)
Number of subjects: 36
Study 33247483 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (up to 40 mg/day) plus Tipepidine (30 mg twice daily)
Number of subjects: 62
Study 33247483 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (up to 40 mg/day) plus Placebo
Number of subjects: 62
Study 32061188 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug
Number of subjects: 0
Study 32061188 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35407385 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 38
Study 35407385 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 38
Study 35407385 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38
Study 32272022 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - budesonide
Number of subjects: 462
Study 32272022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 32272022 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-155-5p and hsa-miR-532-5p
Number of subjects: 462
Study 33186325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg per day
Number of subjects: 85
Study 33186325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 34486579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equation group (116 eyes)
Number of subjects: 174
Study 34486579 — intervention group
Group type: COMPARATOR
Intervention: Verification group (58 eyes)
Number of subjects: 174
Study 34181783 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control exertion (incongruent Stroop task)
Number of subjects: 13
Study 34181783 — intervention group
Group type: COMPARATOR
Intervention: Control (congruent Stroop task)
Number of subjects: 13
Study 32725609 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (watching a video of a walking group)
Number of subjects: 108
Study 32725609 — intervention group
Group type: COMPARATOR
Intervention: Image group (watching a static image of flowers)
Number of subjects: 108
Study 32725609 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 108
Study 32725609 — intervention group
Group type: COMPARATOR
Intervention: Image group
Number of subjects: 108
Study 36001916 — intervention group
Group type: COMPARATOR
Intervention: ABCD training
Number of subjects: 0
Study 36001916 — intervention group
Group type: COMPARATOR
Intervention: UDS training
Number of subjects: 0
Study 36001916 — intervention group
Group type: COMPARATOR
Intervention: All training types
Number of subjects: 0
Study 36001916 — intervention group
Group type: COMPARATOR
Intervention: Dermatological feedback
Number of subjects: 0
Study 36001916 — intervention group
Group type: COMPARATOR
Intervention: Dermatological + Motivational feedback
Number of subjects: 0
Study 33752439 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rule-out pathway using high-sensitivity cardiac troponin I concentrations <5 ng/L at presentation.
Number of subjects: 31492
Study 34347953 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression surgery (decompression-alone group)
Number of subjects: 262
Study 34347953 — intervention group
Group type: COMPARATOR
Intervention: Decompression surgery with instrumented fusion (fusion group)
Number of subjects: 262
Study 34347953 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful fusion
Number of subjects: 262
Study 35865313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=19)
Number of subjects: 38
Study 35865313 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 38
Study 32960309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment of Lisfranc injuries
Number of subjects: 55
Study 32815804 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBPB with 20 cc of 0.25% levobupivacaine + 3.3 mg dexamethasone (group LD)
Number of subjects: 54
Study 32815804 — intervention group
Group type: COMPARATOR
Intervention: ISBPB with 20 cc of 0.25% levobupivacaine (group L)
Number of subjects: 54
Study 36085169 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (< 23 kg/m2)
Number of subjects: 475813
Study 36085169 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (> 30 kg/m2)
Number of subjects: 475813
Study 36085169 — intervention group
Group type: EXPERIMENTAL
Intervention: High AD genetic risk score (AD-GRS) and BMI (< 23 kg/m2)
Number of subjects: 475813
Study 36085169 — intervention group
Group type: COMPARATOR
Intervention: Higher BMI
Number of subjects: 475813
Study 34747093 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological counselling (n=38)
Number of subjects: 71
Study 34747093 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 71
Study 32683388 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) strips as an adjunct to epinephrine impregnated gauze
Number of subjects: 30
Study 32683388 — intervention group
Group type: COMPARATOR
Intervention: Aluminum chloride (Expasyl™)
Number of subjects: 30
Study 35147119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 35147119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34036728 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient‐fortified lipid‐based nutrient supplement containing 250‐μg I per day started immediately after randomization (Arm 1)
Number of subjects: 300
Study 34036728 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient‐fortified lipid‐based nutrient supplement containing 250‐μg I per day started at 12 weeks gestation (Arm 2)
Number of subjects: 300
Study 34036728 — intervention group
Group type: COMPARATOR
Intervention: No intervention supplement (Arm 3)
Number of subjects: 300
Study 32081683 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction (n = 18)
Number of subjects: 56
Study 32081683 — intervention group
Group type: COMPARATOR
Intervention: No traction (n = 38)
Number of subjects: 56
Study 34758350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 427
Study 34758350 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 427
Study 34758350 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage or conservative wait-and-see approach
Number of subjects: 427
Study 34900845 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 2 (second-generation isCGM) with education on using interstitial glucose data
Number of subjects: 100
Study 34900845 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (control group)
Number of subjects: 100
Study 34900845 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 2 (second-generation isCGM)
Number of subjects: 100